2021 Year In Review
Reflecting on the Pursuit to Cure Brain Cancer
As we begin the new year, we would like to take a moment to reflect on some of the accomplishments at the Ivy Brain Tumor Center in 2021.
We launched three new early phase clinical trials with novel strategies/designs, including sonodynamic therapy, pamiparib and niraparib, with industry collaborators SonALAsense, BeiGene and GSK. Our team presented interim data from our studies at international meetings, such as ASCO, EANO, ESMO and SNO. Last year in a major announcement we revealed plans to build a new headquarters for the Ivy Center, and construction is already underway. This investment solidifies our commitment to finding a cure for brain cancer within the next decade.
Take a look at the Ivy Center’s year in review to learn more. We’re excited about all that’s coming in 2022 to help move the needle for brain cancer patients.
Clinician Couple Finds Themselves Faced with an Unimaginable Diagnosis
- January 5, 2021
- Posted in Patient Stories
When Patricia’s glioblastoma came back after her first surgery, both she and her husband knew it was time to start looking at alternative treatment options. After extensive research, they discovered the hope they were looking for was actually right in their backyard at the Ivy Center in Phoenix.
Promising treatment for deadly Glioblastoma being tested on humans at Ivy Brain Tumor Center
- January 15, 2021
- Source: Chamber Business News
A promising non-invasive treatment to effectively and safely destroy deadly brain tumors is being tested on human patients for the first time ever at the Ivy Brain Tumor Center at the Barrow Neurological Institute in Phoenix.
It’s Personal: Dr. Robert F. Spetzler
- February 12, 2021
- Ivy Center
World-renowned neurosurgeon, Dr. Robert F. Spetzler, recalls his sister-in-law’s diagnosis with glioblastoma and the personal connections that guided him through his career.
Ivy Brain Tumor Center, SonALAsense and Insightec Announce the First Patient Dosed in First-in-Human Clinical Trial of Noninvasive Sonodynamic Therapy for the Treatment of Brain Cancer
- March 30, 2021
The Ivy Center is pleased to announce the dosing of its first patient in a first-in-human Phase 0 clinical trial of sonodynamic therapy, a noninvasive drug-device combination developed by SonALAsense in collaboration with Insightec. This historic study aims to develop a nonsurgical treatment option for patients with recurrent glioblastoma and other high-grade gliomas.
Drug Researchers Need to Learn to “Fail Fast”
- March 10, 2021
- Source: Techonomy
In this Techonomy exclusive from Dr. Nader Sanai, director of the Ivy Brain Tumor Center, he discusses the “fail fast” adage associated with Silicon Valley and the implications this method could have on the healthcare industry specifically, in clinical trials.
First Patient Treated in Ivy Brain Tumor Center’s Phase 0 Clinical Trial of Pamiparib in Newly Diagnosed and Recurrent Glioblastoma
- March 10, 2021
The Ivy Brain Tumor Center at Barrow Neurological Institute has announced the first patient has been treated in a Phase 0 clinical trial of pamiparib in newly diagnosed glioblastoma (nGBM) and recurrent glioblastoma (rGBM). This is the first Phase 0 clinical trial open to newly diagnosed glioblastoma patients.
Westy’s Wish: An Open Letter from the Wife of NBA Hall of Famer, Paul Westphal
- April 23, 2021
- Ivy Center
In honor of Brain Tumor Awareness Month, Cindy Westphal, wife of basketball Hall of Famer, Paul Westphal, recalls her husband’s journey with glioblastoma and asks for your support of the Ivy Brain Tumor Center’s mission to contribute to a cure for brain cancer within this decade.
Arizona Recognizes Brain Tumor Awareness Month
- May 6, 2021
- Source: Office of the Governor Doug Ducey
Governor Doug Ducey declared May to be Brain Tumor Awareness Month to promote education of the condition, recognize the medical professionals who combat the issue, highlight the significant progress in research, and honor the families who have been impacted.
Ivy Brain Tumor Center Announces Interim Results from a Phase 0 ‘Trigger’ Trial of Targeted Combination Therapy for Glioblastoma
- June 4, 2021
The Ivy Brain Tumor Center has announced initial results from an ongoing, dual-drug Phase 0 study evaluating the tumor pharmacokinetics (PK) and tumor pharmacodynamics (PD) of abemaciclib, a selective CDK4/6-inhibitor, plus LY3214996, a selective ERK1/2 inhibitor, in recurrent glioblastoma patients.
Making a Difference on Glioblastoma Awareness Day 2022
- July 1, 2021
- Ivy Center
Glioblastoma Awareness Day (GBM Day) is dedicated to increasing public awareness of glioblastoma brain cancer.
Ivy Brain Tumor Center Announces Plan to Build New Global Headquarters in Phoenix
- July 21, 2021
The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest Phase 0 clinical trials program for aggressive brain tumors, announced its plans for a new 75,000-square-foot headquarters, with construction beginning in August. The five-story building will be the largest translational research center dedicated to brain tumor drug development in the world.
In Arizona, The Fight Against Brain Cancer is Personal
- August 25, 2021
- Posted in Glioblastoma
Even as someone whose resilient spirit had been the hallmark of their public image, Senator John McCain was sadly no match for glioblastoma. On the second anniversary of his passing, we honor McCain’s legacy by continuing to push for increased awareness and support for research so others can have a fighting chance at this deadly disease.
Ivy Brain Tumor Center and SonALAsense Announce Positive Initial Results of the First-in-Human Phase 0/1 Clinical Trial of Non-Invasive Sonodynamic Therapy for Recurrent Glioblastoma
- September 20, 2021
The Ivy Brain Tumor Center’s clinical trial of sonodynamic therapy provides proof of concept for this new metabolically targeted, rapidly acting technology platform for brain tumors
Ivy Brain Tumor Center Announces Results from Phase 0/1 Clinical Trial of Ribociclib Plus Everolimus in Recurrent High-Grade Glioma
- September 9, 2021
Published in the journal of Neuro-Oncology and presented at the European Association of Neuro-Oncology, the Ivy Brain Tumor Center announced results from their Phase 0/1 clinical trial of ribociclib plus everolimus in patients with high-grade glioma (HGG).
Diamondbacks GM Mike Hazen and wife give back to support cancer research
- December 20, 2021
- Source: AZFamily
The Hazen’s presented a $1.5 million check to doctors, physicians and researchers at the Ivy Brain Tumor Center at the Barrow Neurological Institute. Nicole is receiving treatment and care at the Ivy Center after she was diagnosed in July 2020 with glioblastoma, a rare form of brain cancer.
Robust 2022 Glioblastoma Clinical Trials Program Offers Brain Cancer Patients New Treatment Options
- February 15, 2022
- Posted in Clinical Trials
Our team of brain tumor experts have compiled everything you need to know about our clinical trials, including the rationale behind the novel drugs and devices we’re investigating as well as some of the initial results we’re seeing in brain cancer patients.
Ivy Brain Tumor Center Collaborates with GSK on New Phase 0 Clinical Trial to Evaluate Niraparib in Patients with Brain Cancer
- November 2, 2021
The Ivy Center in collaboration with UCSF Department of Neurological Surgery is pleased to announce a new clinical trial of GSK’s niraparib (ZEJULA) – an FDA-approved drug to treat ovarian cancer – for patients with newly diagnosed glioblastoma and recurrent high-grade gliomas.
Ivy Brain Tumor Center To Present 11 Abstracts at the 2021 SNO Annual Meeting
- November 18, 2021
- Posted in Clinical Trials
At the 26th Annual Meeting of the Society for Neuro-Oncology (SNO), the Ivy Brain Tumor Center’s team of brain tumor specialists and scientists will be giving 11 presentations based on our preclinical and clinical research findings. The abstracts were published in the journal of Neuro-Oncology.
StacheStrong Raises $340,000 for the Ivy Brain Tumor Center’s Innovative Phase 0 Clinical Trial of Sonodynamic Therapy for Patients with Glioblastoma
- December 1, 2021
StacheStrong, a non-profit devoted to raising funds and awareness for brain cancer research, announced they raised $340,000 for the Ivy Brain Tumor Center at Barrow Neurological Institute.